Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Merck KGaA :, Darmstadt, Germany, Licenses Four Oncology Research and Development Programs from Vertex and Becomes a Leader in DNA Damage and Repair

share with twitter share with LinkedIn share with facebook
share via e-mail
01/19/2017 | 07:38pm CET

By a News Reporter-Staff News Editor at Drug Week -- Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its biopharmaceutical business in the US and Canada as EMD Serono, announced that it has entered into a licensing agreement with Vertex Pharmaceuticals Incorporated, Boston, USA, for the worldwide development and commercialization of four promising research and development programs that represent novel approaches to the treatment of cancer (see also Pharmaceutical Companies).

"With this strategic deal, we significantly strengthen our oncology pipeline in two attractive areas where we have leading competence, DNA damage and repair and immuno-oncology-areas which also have promising therapeutic synergy," says Belen Garijo, CEO Healthcare and Member of the Executive Board of Merck KGaA, Darmstadt, Germany. "This deal underscores our commitment to accelerate innovation for cancer patients, and we are excited for the opportunity to build on Vertex's rigorous science and advance these leading programs."

As part of the agreement, Merck KGaA, Darmstadt, Germany will license two clinical-stage programs targeting DNA damage and repair, along with two additional novel pre-clinical programs. Vertex will receive an upfront payment of $230 million, in addition to royalties on future net sales. Merck KGaA, Darmstadt, Germany will assume full responsibility for the development and commercialization of all the programs.

"The Vertex R&D team has produced a portfolio of first-in-class compounds with the potential to enhance the therapy of multiple cancers," said Jeffrey Leiden, Chairman, President and CEO of Vertex. "We are pleased to partner with Merck KGaA, Darmstadt, Germany, a leader in oncology with exciting complementary assets that will help fully realize the value of these unique compounds and accelerate the programs' potential benefits for patients."

Keywords for this news article include: Pharmaceutical Companies, Genetics, Oncology, DNA Damage, Proteomics, DNA Research, Deoxyribonucleic Acid, Merck KGaA Darmstadt Germany.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
01/19 MERCK KGAA : Darmstadt, Germany, Licenses Four Oncology Research and Development..
01/19 MERCK KGAA : Darmstadt, Germany Licenses Four Oncology Research and Development ..
01/14 VERTEX PHARMACEUTICALS INCORPORATED : Merck expands oncology portfolio with four..
01/12 VERTEX PHARMACEUTICALS INCORPORATED : Announces Upcoming Presentation at the J.P..
01/12 VERTEX PHARMACEUTICALS INCORPORATED : Patent Issued for Methods of Regioselectiv..
01/11 VERTEX PHARMACEUTICALS INCORPORATED : VRTX) Files An 8-K Entry into a Material ..
01/11 VERTEX PHARMACEUTICALS INC / MA : Entry into a Material Definitive Agreement (fo..
01/11 VERTEX PHARMACEUTICALS INCORPORATED : Merck KGaA, Darmstadt, Germany Licenses Fo..
01/09 VERTEX PHARMACEUTICALS INCORPORATED : VRTX) Files An 8-K Results of Operations ..
01/09 VERTEX PHARMACEUTICALS INCORPORATED : INC / MA Results of Operations and Financi..
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
01/20 Concert Pharma's CTP-656 an Orphan Drug for cystic fibrosis; shares up 8% pre..
01/17 Concert Pharma to add additional step in mid-stage study of CF candidate CTP-..
01/13 2016 : A Record Year
01/12 Vertex And German Merck Find Their Perfect Fit
01/12 JPMorgan Day Three Roundup - Trump Reminds The Sector Who's In Charge
Financials ($)
Sales 2016 1 695 M
EBIT 2016 237 M
Net income 2016 -131 M
Finance 2016 502 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 106,32
EV / Sales 2016 11,6x
EV / Sales 2017 9,35x
Capitalization 20 182 M
More Financials
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 99,4 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith EVP, Chief Operating & Financial Officer
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Joshua S. Boger Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.5.79%115 062
ACTELION LTD4.58%23 977
More Results